MX2024012948A - Formulacion intravenosa que contiene istaroxima para el tratamiento del choque precardiogenico y del choque cardiogenico - Google Patents
Formulacion intravenosa que contiene istaroxima para el tratamiento del choque precardiogenico y del choque cardiogenicoInfo
- Publication number
- MX2024012948A MX2024012948A MX2024012948A MX2024012948A MX2024012948A MX 2024012948 A MX2024012948 A MX 2024012948A MX 2024012948 A MX2024012948 A MX 2024012948A MX 2024012948 A MX2024012948 A MX 2024012948A MX 2024012948 A MX2024012948 A MX 2024012948A
- Authority
- MX
- Mexico
- Prior art keywords
- shock
- istaroxime
- cardiogenic shock
- precardiogenic
- treatment
- Prior art date
Links
- 206010007625 cardiogenic shock Diseases 0.000 title abstract 7
- MPYLDWFDPHRTEG-PAAYLBSLSA-N (3e,5s,8r,9s,10r,13s,14s)-3-(2-aminoethoxyimino)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-6,17-dione Chemical compound C1\C(=N\OCCN)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=O)[C@H]21 MPYLDWFDPHRTEG-PAAYLBSLSA-N 0.000 title abstract 4
- 229950005528 istaroxime Drugs 0.000 title abstract 4
- 238000001990 intravenous administration Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 230000035939 shock Effects 0.000 title 1
- 238000001802 infusion Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263332909P | 2022-04-20 | 2022-04-20 | |
| PCT/US2023/018998 WO2023205183A1 (en) | 2022-04-20 | 2023-04-18 | Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012948A true MX2024012948A (es) | 2024-11-08 |
Family
ID=86331896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012948A MX2024012948A (es) | 2022-04-20 | 2024-10-21 | Formulacion intravenosa que contiene istaroxima para el tratamiento del choque precardiogenico y del choque cardiogenico |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4511040A1 (enExample) |
| JP (1) | JP2025513337A (enExample) |
| KR (1) | KR20250005343A (enExample) |
| CN (1) | CN119156218A (enExample) |
| AU (1) | AU2023256547A1 (enExample) |
| CA (1) | CA3248625A1 (enExample) |
| IL (1) | IL316164A (enExample) |
| MX (1) | MX2024012948A (enExample) |
| WO (1) | WO2023205183A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025128432A1 (en) * | 2023-12-11 | 2025-06-19 | Windtree Therapeutics, Inc. | Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1079807A (en) | 1912-09-25 | 1913-11-25 | Jonathan S Snyder | Coat-closure. |
| NL95803C (enExample) | 1953-12-31 | 1900-01-01 | ||
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
| US5874268A (en) | 1996-09-23 | 1999-02-23 | Duke University | Method of introducing exogenous compounds into cells by electroporation and apparatus for same |
| CN1261791A (zh) | 1997-07-02 | 2000-08-02 | Sdg有限公司 | 诊断或治疗用途的靶向脂质体构建物 |
| SE9704076D0 (sv) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
| WO2005063156A1 (en) | 2003-12-22 | 2005-07-14 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
| KR20060123384A (ko) | 2003-12-24 | 2006-12-01 | 가부시키가이샤 엘티티 바이오파마 | 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제 |
| US20070082042A1 (en) | 2004-08-06 | 2007-04-12 | Deok-Hoon Park | Multiple-layered liposome and preparation method thereof |
| EP1812074B1 (en) | 2004-10-18 | 2010-12-29 | Nitto Denko Corporation | Intracellular peptide delivery |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| CN103315968B (zh) | 2013-06-26 | 2015-04-01 | 中国生命药物治疗有限公司 | 一种注射用粉针剂及其制备方法 |
| CN112118846B (zh) | 2019-03-05 | 2024-04-16 | 风树疗法公司 | 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂 |
-
2023
- 2023-04-18 CA CA3248625A patent/CA3248625A1/en active Pending
- 2023-04-18 KR KR1020247038640A patent/KR20250005343A/ko active Pending
- 2023-04-18 EP EP23723312.7A patent/EP4511040A1/en active Pending
- 2023-04-18 JP JP2024561787A patent/JP2025513337A/ja active Pending
- 2023-04-18 IL IL316164A patent/IL316164A/en unknown
- 2023-04-18 CN CN202380035206.5A patent/CN119156218A/zh active Pending
- 2023-04-18 WO PCT/US2023/018998 patent/WO2023205183A1/en not_active Ceased
- 2023-04-18 AU AU2023256547A patent/AU2023256547A1/en active Pending
-
2024
- 2024-10-21 MX MX2024012948A patent/MX2024012948A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4511040A1 (en) | 2025-02-26 |
| JP2025513337A (ja) | 2025-04-24 |
| WO2023205183A1 (en) | 2023-10-26 |
| CA3248625A1 (en) | 2023-10-26 |
| AU2023256547A1 (en) | 2024-11-28 |
| KR20250005343A (ko) | 2025-01-09 |
| IL316164A (en) | 2024-12-01 |
| CN119156218A (zh) | 2024-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gawarammana et al. | Parallel infusion of hydrocortisone±chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites | |
| Petrides et al. | Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature | |
| Shaikh et al. | Applications of steroid in clinical practice: a review | |
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| Sticherling | Systemic sclerosis–the dermatological perspective | |
| BR112022015996A2 (pt) | Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 | |
| AR129461A1 (es) | Extracto de plectranthus amboinicus para usar en la inhibición de respuestas inmunitarias | |
| Fu et al. | Fu's subcutaneous needling for orthostatic hypotension due to Guillain-Barré syndrome: A case report | |
| BR112022025741A2 (pt) | Usos de composições compreendendo crofelemer para tratamento de diarreia induzida por quimioterapia (cid) | |
| BR112022006329A2 (pt) | Método de tratamento de pacientes com síndrome hepatorrenal tipo 1 e pressão arterial média baixa | |
| PATEL et al. | Rifampicin-induced Stevens-Johnson Syndrome: A Rare Case Report. | |
| Aleshkina et al. | The clinical characteristic of acute brief psychotic disorders with symptoms of schizophrenia | |
| Kazmi et al. | Use of Intravenous Vitamin C in Severe COVID led to reduction in ICU stay and severity of Disease | |
| Simadibrata et al. | Propofol Sedation in Diagnostic Upper Gastrointestinal Endoscopy | |
| KR100650451B1 (ko) | 아토피성 피부염에 치료효과를 갖는 약독화된 살모넬라균주 | |
| Amini et al. | Does pethidine hydrochloride analgesia in patients with acute appendicitis alter the diagnostic accuracy of clinical evaluation: a randomized double-blind clinical trial | |
| Titanji et al. | Use of Baricitinib in Patients With Moderate to Severe Coronavirus | |
| Bodnar et al. | Effective Treatment against SARS-Cov-2 with Amantadine Hydrochloride | |
| Gałązka et al. | Usage of pregabalin in the treatment of pain associated with chronic pancreatitis–a clinically oriented narrative review | |
| Abd El-Hameed et al. | Comparative Study of the Prognosis of Patients with Septic Shock Related to Ventilator Associated Pneumonia Using Variance of Arterial and Venous CO2 versus Serum Lactate | |
| WO2025264860A3 (en) | Methods of treating post-covid airway disease | |
| AHMAD et al. | A Comparison of Lidocaine and Ketamine for prevention withdrawal from injection of Rocuronium | |
| Singh et al. | Comparative study of Ringer’s lactate solution and 6% hydroxyethyl starch solution as pre-loading fluid for prevention of hypotension following spinal anesthesia | |
| Tateyama | Studies on Cerebral Circulation and Metabolism in Hypertensive Diseases III. The Effect of Prolonged Oral Administration of Hypotensive Agents upon the Cerebral Circulation and Metabolism in Patients with Essential Hypertension |